Coronary artery bypass surgery hormonal manipulation: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Coronary artery bypass surgery}} | |||
{{CMG}} | {{CMG}} | ||
| Line 17: | Line 17: | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Postmenopausalhormonaltherapy([[estrogen]]/[[prosgesterone]])shouldnot be administered to women undergoing CABG ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Postmenopausalhormonaltherapy([[estrogen]]/[[prosgesterone]])shouldnot be administered to women undergoing CABG ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|} | |} | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
| Line 23: | Line 24: | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==References== | |||
{{reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Cardiac surgery]] | |||
[[Category:Cardiology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 17:29, 1 November 2016
|
Coronary Artery Bypass Surgery Microchapters | |
|
Pathophysiology | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Perioperative Monitoring | |
|
Surgical Procedure | |
|
Special Scenarios | |
|
Coronary artery bypass surgery hormonal manipulation On the Web | |
|
Coronary artery bypass surgery hormonal manipulation in the news | |
|
Blogs on Coronary artery bypass surgery hormonal manipulation|- |
|
|
Directions to Hospitals Performing Coronary artery bypass surgery hormonal manipulation | |
|
Risk calculators for Coronary artery bypass surgery hormonal manipulation | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]
Coronary artery bypass surgery hormonal manipulation
| Class I |
| "1. Use of continuous intravenous insulin to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding hypoglycemia is indicated to reduce the incidence of adverse events, including deep sternal wound infection, after CABG (Level of Evidence: B)" |
| Class III: HARM |
| "1. Postmenopausalhormonaltherapy(estrogen/prosgesterone)shouldnot be administered to women undergoing CABG (Level of Evidence: B)" |
| Class IIb |
| "1. The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness (Level of Evidence: B)" |
References
- ↑ Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.